LUCD
Healthcare Medical DevicesLucid Diagnostics Inc.
$0.63
-0.01 -2.03% today
Price History
Not enough data
Key Stats
Market Cap
119.72M
Avg Volume
1.33M
EPS
-$0.41
52W High
$1.63
52W Low
$0.50
Div. Yield
0.0%
Analyst Ratings
Buy2
Str Buy
3
Buy
0
Hold
0
Sell
0
Str Sell
Valuation
Forward P/E
-3.80
P/B Ratio
11.01
P/S Ratio
22.00
EV/EBITDA
-2.21
EV/Revenue
20.24
Margins
Gross Margin (21.7%)
Operating Margin (868.5%)
Net Margin 0.0%
EBITDA Margin 0.0%
Growth & Returns
Revenue Growth (YoY)
26.7%
Return on Equity
(556.3%)
Return on Assets
(81.6%)
Liquidity & Leverage
Current Ratio
1.33
Quick Ratio
1.29
Debt / Equity
2.28
Total Cash
34.47M
Total Debt
24.91M
About
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
www.luciddx.com